New SARS-CoV-2 variant binds cells more efficiently but remains vulnerable to current booster

Low-Res_Pöhlmann_Hoffmann_DSC_4422

The emerging SARS-CoV-2 variant PJ.2.1 appears better able to bind the ACE2 receptor and enter some human cells, which may help explain its spread. Encouragingly, antibodies generated by the current XFG-adapted booster still neutralised the variant effectively in laboratory tests.

 Registered users, subscribers or members - SIGN IN

To continue reading this article

Membership

Included as a benefit

Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.

I AM A MEMBER

Find out more about how to join.

 

Register

FREE

Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.

REGISTER

 

Subscribe

3.75 per month / £35 annually

Get unlimited access to The Microbiologist.

SUBSCRIBE